Bivalent HPV vaccine shows benefit for recalcitrant warts

  • J Am Acad Dermatol

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Intralesional or intramuscular administration of a recombinant bivalent human papillomavirus (HPV) vaccine (Ceravix) appears effective for the treatment of patients with multiple recalcitrant common warts.

Why this matters

  • Warts are often recalcitrant to common treatments, necessitating new options.

Key results

  • 81.8% of patients treated with intralesional bivalent HPV vaccine and 63.3% of patients treated with intramuscular bivalent HPV vaccine achieved complete clearance (P=.287).
  • The clearance rate was faster in the intralesional group compared with the intramuscular group (3.22 vs 4.57 months; P=.005).
  • All patients reported tolerable pain at the injection site.
  • Localized itching was reported in 90.9% of the intralesional group and 95.5% of the intramuscular group.
  • No recurrences were reported during a 6-month follow-up.

Study design

  • 44 patients with recalcitrant multiple common warts (>2 years duration with no response to ≥2 treatment modalities), 22 who received intralesional bivalent HPV vaccine and 22 who received intramuscular bivalent HPV vaccine, were included.
  • Funding: None.

Limitations

  • Small sample size.
  • No control group.